CCTG Trials in Development – Q1 2026

The Q12026 quarterly update for pending CCTG trials and approximate activation timelines are listed below. For more information between the quarterly updates, find the most recent updates and stories of recently opened CCTG trials here: https://www.ctg.queensu.ca/public/trials-development.

ALC9 (HEMATOLOGIC) - Expected: Q3 2026
myeloMATCH - (ERASE) Eradicating MRD in Patients with AML prior to Stem Cell Transplant 

ALC10 (HEMATOLOGIC) – Expected: Q2 2026
myeloMATCH - Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML

ALC11 (HEMATOLOGIC) - Expected: Q3 2026 
myeloMATCH - ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML 

MD1 (HEMATOLOGIC) - Expected: Q2 2026
myeloMATCH – (CALMS) Combination Therapy with Luspatercept in Lower Risk MDS 

BR39 (LUNG) – Expected: Q4 2026
(LUNA-2): LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial Q4 2026

HN14 (HEAD & NECK) - Expected: Q3 2026 
(REVERT) Delayed Reduced Volume and Dose Elective Ratiotherapy in Patients with HNSCC

LYC2 (LYMPHOMA) – Expected: Q2 2026
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

ME18 (MELANOMA) - Expected: Q1 2027 
(MSLT-3) The Multicentre Selective Lymphadenectomy Trial-3 - Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma

PAC5 (GASTROINTESTINAL) - Expected: 2026 
Lanreotide for the Prevention of Postoperative Pancreatic Fistula

SC31 (SUPPORTIVE CARE) – Expected: Q2 2026
(TEMPO) Using SMART to optimize the stepped care delivery of a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers

SR8 (SARCOMA) - Expected: Q1 2027 
(NAPStAR) NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma 

MA42 (BREAST) - Expected: Q2 2026 
(NoLEEta) No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib

EN12 (GYNECOLOGY) – Expected: Q3 2026
(RAINBO-ORANGE) Treatment of Endometrial Cancer Based on Molecular Features

IND246 (SELECTED SOLID TUMORS) – Expected: Q2 2026 
(GCAR1) A chimeric antigen receptor (CAR) t-cell therapy in selected relapsed/refractory GPNMB-expressing alveolar soft-part sarcoma, renal cell carcinoma, and triple negative breast cancer

IND245 (MANTLE CELL LYMPHOMA) – Expected: Q2 2026 
Sonrotoclax and Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma receiving standard of care CAR-t cell therapy

IND241E (METASTATIC BREAST CANCER) – Expected: Q2 2026
A phase II study of CFI-402257 in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancer

IND241F(METASTATIC BREAST CANCER) – Expected: Q2 2026
A phase II study of CFI-400945 in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancer

IND241G (METASTATIC BREAST CANCER) – Expected: Q2 2026
A phase II study of sacituzumab govitecan in patients with CDK4/6 inhibitor treated ER+/HER2- metastatic breast cancer

Opened Q1 2026

SC30 (SUPPORTIVE CARE) 

(RATIONAL-PT) Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial | Find out more >

SC32S (SUPPORTIVE CARE) 

Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials | Find out more>

CE10 (BRAIN) 

(VIGOR) Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma | Find out more>